BidaskClub upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday morning.
A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Tandem Diabetes Care from a buy rating to a hold rating in a research note on Saturday, April 7th. ValuEngine upgraded Tandem Diabetes Care from a sell rating to a hold rating in a report on Saturday, April 7th. Oppenheimer set a $8.00 price target on Tandem Diabetes Care and gave the stock a buy rating in a report on Friday, April 6th. Cowen upgraded Tandem Diabetes Care from a market perform rating to an outperform rating in a report on Wednesday, March 28th. Finally, Robert W. Baird upgraded Tandem Diabetes Care from a neutral rating to an outperform rating in a report on Friday, March 23rd. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $9.16.
Shares of TNDM opened at $7.01 on Wednesday. Tandem Diabetes Care has a 52-week low of $2.14 and a 52-week high of $12.20. The company has a debt-to-equity ratio of -2.63, a current ratio of 1.78 and a quick ratio of 1.03.
In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff purchased 750,000 shares of the stock in a transaction dated Friday, February 9th. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Dick Allen purchased 25,539 shares of the stock in a transaction dated Tuesday, March 6th. The shares were acquired at an average price of $3.88 per share, with a total value of $99,091.32. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 850,539 shares of company stock valued at $1,749,091. Company insiders own 20.90% of the company’s stock.
An institutional investor recently raised its position in Tandem Diabetes Care stock. Vanguard Group Inc. boosted its position in shares of Tandem Diabetes Care (NASDAQ:TNDM) by 2.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,233,607 shares of the medical device company’s stock after acquiring an additional 32,991 shares during the quarter. Vanguard Group Inc. owned 2.46% of Tandem Diabetes Care worth $987,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.74% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/12/tandem-diabetes-care-tndm-upgraded-by-bidaskclub-to-strong-buy.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.